Sustained-release morphine for epidural analgesia in rats

Area of Science:

• Pharmacology
• Drug Delivery Systems
• Pain Management

Background:

• Epidural opioid analgesia typically involves frequent administration, posing risks like infection and requiring significant healthcare resources.
• Concerns regarding respiratory depression limit the safety and efficacy of conventional epidural opioids.
• Developing sustained-release formulations aims to improve patient convenience and safety profiles.

Purpose of the Study:

• To evaluate the efficacy and safety of a single epidural dose of sustained-release morphine (DTC401) in rats.
• To compare the analgesic duration and toxic effects of DTC401 with standard epidural morphine sulfate.
• To assess the pharmacokinetic profile of DTC401 in cerebrospinal fluid and serum.

Main Methods:

• Sustained-release morphine (DTC401) was formulated using a lipid-based DepoFoam delivery system.
• Analgesia was assessed using the hot-plate test; toxicities were evaluated via pulse oximetry, corneal-reflex testing, and catalepsy observation.
• Pharmacokinetic studies involved measuring drug concentrations in cerebrospinal fluid and serum using radioimmunoassay.

Main Results:

• DTC401 provided analgesia with a similar onset but significantly longer duration compared to morphine sulfate.
• Minimal decreases in hemoglobin oxygen saturation and low incidences of catalepsy and corneal-reflex loss were observed with DTC401, even at high doses.
• Morphine sulfate at higher doses caused significant decreases in oxygen saturation and notable toxic effects.

Conclusions:

• A single epidural administration of DTC401 offers prolonged analgesia in rats.
• DTC401 demonstrates a favorable safety profile with minimal supraspinal toxic effects compared to morphine sulfate.
• Sustained-release epidural morphine holds potential for improved pain management strategies.